Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2026 Jan:232:116120.
doi: 10.1016/j.ejca.2025.116120. Epub 2025 Nov 28.

Waldenström's macroglobulinemia: The LYSA pragmatic guidelines

Damien Roos-Weil  1 , Cécile Tomowiak  2 , Stéphanie Poulain  3 , Florence Nguyen-Khac  4 , Florian Bouclet  5 , Marine Armand  4 , Thérèse Aurran  6 , Eric Durot  7 , David Ghez  8 , Bénédicte Hivert  9 , Kamel Laribi  10 , Magali Le Garff Tavernier  4 , Stéphane Lepretre  5 , Lydia Montes  11 , Amine Moslemi  12 , Laurence Simon  13 , Véronique Leblond  14 , Pierre Morel  11 , Olivier Tournilhac  15
Affiliations
Free article
Practice Guideline

Waldenström's macroglobulinemia: The LYSA pragmatic guidelines

Damien Roos-Weil et al. Eur J Cancer. 2026 Jan.
Free article

Abstract

Waldenström's macroglobulinemia (WM) is a rare, indolent B-cell lymphoma that predominantly affects older adults. In recent years, significant progress has been made in understanding its pathogenesis, identifying relevant biomarkers, and developing novel therapeutic approaches to complement traditional chemoimmunotherapy-collectively reshaping the management landscape of WM. In this article, we provide comprehensive, evidence-based recommendations for the diagnosis, molecular evaluation, and treatment of WM, including strategies for both frontline and relapsed disease. These guidelines are informed by the latest clinical research, expert consensus, and current practice standards, with the goal of equipping clinicians with a practical and effective framework for delivering optimal care to patients with WM.

Keywords: BTK inhibitors; Chemoimmunotherapy; Guidelines; Mutations; Waldenström’s macroglobulinemia.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest DRW: Abbvie, Astrazeneca, BeOne, Johnson and Johnson, Lilly (consulting); CT: Johnson and Johnson, Astrazeneca, BeOne, Abbvie, Lilly (consulting); DG: Abbvie, BeiGene/BeOne, Johnson and Johnson, Lilly (travel expense); BeiGene/BeOne (grant); BeiGene/BeOne, Lilly (consulting); ED: Roche, AbbVie, Johnson and Johnson (travel expense); FB: Johnson and Johnson, Abbvie, Astrazeneca (consulting); BeOne, Johnson and Johnson, Chugai (travel expense). KL: Sanofi, Astra-Zeneca, Johnson and Johnson, Abbvie (grants), Abbvie, BeiGene/BeOne, Takeda, BMS, GSK, Amgen, Johnson and Johnson, Pfizer (consulting). VL: BeiGene/BeOne (consulting). The other authors declare no potential conflict of interest

Publication types

MeSH terms

LinkOut - more resources